Former President, Chief Executive Officer and Director · Viridian Therapeutics, Inc. (VRDN)

Jonathan Violin

A named executive officer of Viridian Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,211,072

Salary $59,209Stock awards $0

FY2022: $4,646,740

5th of 5 named executive officers at Viridian Therapeutics by FY2023 total.

5 named officers on file for Viridian Therapeutics, FY2023

Jonathan Violin’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • VRDN’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Viridian Therapeutics’s whole pay program stands against its peers

  • Viridian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRDN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Jonathan Violin’s full pay file as a PDF — free

More than this page: up to 10 years of Jonathan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jonathan Violin compensation by year

Viridian Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Viridian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$567,000$601,200$59,209
Bonus$408,240$288,576$0
Stock awards$0$0$0
Option awards$16,424,277$3,754,644$1,587,151
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$9,021$2,320$564,712
Total$17,408,538$4,646,740$2,211,072

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-115928, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001193125-24-115928. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$17.4M
$4.6M
$2.2M
FY21
FY22
FY23
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option8,031—$0.15
Option33,339—$23.03
Option11,666—$18.51

Per the Outstanding Equity Awards at Fiscal Year-End table in Viridian Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Viridian Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Scott MyersFormer President, Chief Executive Officer and Director$36,407,990
Stephen MahoneyPresident, Chief Executive Officer$12,479,521
Seth HarmonSenior Vice President of Finance and Accounting$6,548,526
Thomas BeethamChief Operating Officer$4,761,401
Jonathan Violin · this pageFormer President, Chief Executive Officer and Director$2,211,072

Board service

Viridian Therapeutics board · FY2023

How this board is paid

Company policy: Viridian Therapeutics pays directors a $40,000 cash retainer. As stated in Viridian Therapeutics's FY2023 proxy.

The full Viridian Therapeutics compensation record

free company brief

This page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Viridian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jonathan Violin's compensation dossier · One-time report. No refunds.